Price Prediction

Moderna (MRNA) Stock Price Prediction: Sales beat lifts the setup, but momentum is still repairing

Moderna (MRNA) is trading at $214.40, below its short- and medium-term moving averages after a 2.34% 24-hour decline, even as recent third-quarter results and raised revenue guidance supported a sh...

Moderna (MRNA) Stock Price Prediction: Sales beat lifts the setup, but momentum is still repairing

What changed

Moderna (MRNA) is trying to digest a strong fundamental update against a softer tape. On November 6, Moderna said third-quarter 2026 revenue grew 29% to $1.3 billion, cash costs fell 10% to $1.0 billion, and it was profitable, while raising full-year 2026 revenue guidance to 15% to 25% growth from a prior outlook of up to 10% growth. Piper Sandler followed on November 9 by lifting its price target to $305 from $230 and keeping an Overweight rating, citing third-quarter product sales of $1.27 billion and the higher revenue outlook. Goldman Sachs also raised its target to $195 on November 12 while staying Neutral, pointing to the same revenue beat and upside to consensus on EPS. citeturn0search0turn0search1turn0search2turn0search3

Price action and trend read

Against that backdrop, the stock is not in a clean breakout. MRNA last traded at $214.40 after a 2.34% 24-hour drop, with the recent session showing a range of $223.89 to $212.23. The share price is below the 7-day SMA of $224.11, the 20-day SMA of $234.48, the 12-day EMA of $228.54, and the 26-day EMA of $227.41. That keeps the short-term structure in distribution mode, even though the stock remains above the 50-day SMA of $219.39 by a narrow margin. citeturn0search1

Key levels traders are watching

The most relevant pivot is $216.84. Above that, the first checkpoint is $221.45, then $228.50, which would start to repair the short-term trend and challenge the move back toward the 20-day average at $234.48. On the downside, immediate support sits at $209.79, with stronger support at $205.18. The Bollinger middle band is $234.48, the lower band is $199.04, and %B at 0.2167 shows the stock is still positioned in the lower part of its recent range rather than pressing the upper band. ATR(14) of $18.51 suggests swings remain wide enough that a single day can move through multiple levels quickly. citeturn0search1

Derivatives positioning is slightly defensive

Binance perpetual futures are not flashing panic, but they are leaning cautious. Funding is neutral at 0.0000%, open interest is 15,951 contracts, and open interest value is $3.36 million, with 24-hour OI up 2.71%. The 1-hour global long/short ratio is 0.8734, and top-trader accounts are 47.3% long versus 52.7% short. That is a mild short bias, but not an extreme one. Taker flow is close to balanced at 1.0136, with buy volume of 457 against sell volume of 451, which argues against a one-sided momentum squeeze right now. citeturn0search1

Scenario framing

If Moderna can reclaim the $221.45 to $228.50 zone, the chart would begin to absorb the recent decline and shift attention back toward the 20-day average. If it loses $209.79, the next area that matters is $205.18, with the Bollinger lower band at $199.04 as a broader mean-reversion reference. The current setup is less about a decisive trend call and more about whether the market wants to fade the post-earnings strength or rebuild a higher base after the guidance reset. citeturn0search1turn0search2turn0search3

Sign in to save this article Free account: build your research collection and return to read it anytime.